dangers of glp 1 drugs Exploring the Side Effects GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning Best Practices for Managing Common

R.AroraA.ShippenD

Click here to read the expert reaction to the BMJ article: Click here to read the BMJ article: Science Media Centre University of East London Wegovy(semaglutide) HCP Mounjaro (tirzepatide) HCP To view or add a comment, sign in Despite substantial weight loss, most obesity drugs such as Wegovy and Mounjaro do not meaningfully improve quality of life and few show cardiovascular benefits at one year, finds a new study in The BMJ Greater weight loss was consistently accompanied by higher rates of side effects and treatment discontinuation, which the authors say indicates a clear benefit-harm trade-off

Though the normal intestinal microbiome does not include large amounts of pathogenic organisms, as an example, increased proliferation of the pathogen Clostridium botulinum is associated with release of botulinum neurotoxins, damaging the intestinal barrier and fostering absorption of the neurotoxin into the systemic circulation and the nervous system, causing botulism [49]

RSV-induced MnSOD also reduces oxidative stress (Li et al., 2020a)

J Am Coll Cardiol 71:6984